Literature DB >> 34106040

Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.

Adoración Navarro-Torné1, Eva Agostina Montuori2, Vasiliki Kossyvaki3, Cristina Méndez1.   

Abstract

The aim was to summarize pneumococcal disease burden data among adults in Southern Europe and the potential impact of vaccines on epidemiology. Of 4779 identified studies, 272 were selected. Invasive pneumococcal disease (IPD) incidence was 15.08 (95% CI 11.01-20.65) in Spain versus 2.56 (95% CI 1.54-4.24) per 100,000 population in Italy. Pneumococcal pneumonia incidence was 19.59 (95% CI 10.74-35.74) in Spain versus 2.19 (95% CI 1.36-3.54) per 100,000 population in Italy. Analysis of IPD incidence in Spain comparing pre-and post- PCV7 and PCV13 periods unveiled a declining trend in vaccine-type IPD incidence (larger and statistically significant for the elderly), suggesting indirect effects of childhood vaccination programme. Data from Portugal, Greece and, to a lesser extent, Italy were sparse, thus improved surveillance is needed. Pneumococcal vaccination uptake, particularly among the elderly and adults with chronic and immunosuppressing conditions, should be improved, including shift to a higher-valency pneumococcal conjugate vaccine when available.

Entities:  

Keywords:  Greece; Italy; PCV13; Pneumococcal disease burden; Portugal; Spain; adults; incidence; pneumococcal vaccine; surveillance

Mesh:

Substances:

Year:  2021        PMID: 34106040      PMCID: PMC8437551          DOI: 10.1080/21645515.2021.1923348

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   4.526


  249 in total

1.  Role of laboratories in population-based surveillance of invasive diseases in Lazio, Italy, 1998-2000.

Authors:  A Faustini; E Fabrizi; M Sangalli; E Bordi; P Cipriani; E Fiscarelli; C A Perucci
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-11-09       Impact factor: 3.267

2.  Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.

Authors:  B Rosón; J Carratalà; F Tubau; J Dorca; J Liñares; R Pallares; F Manresa; F Gudiol
Journal:  Microb Drug Resist       Date:  2001       Impact factor: 3.431

3.  Community-Acquired Pneumonia in Elderly Adults with Type 2 Diabetes Mellitus.

Authors:  Diamantis P Kofteridis; Giannoula Giourgouli; Marina N Plataki; Angeliki M Andrianaki; Sofia Maraki; John A Papadakis; Maria E Zacharioudaki; George Samonis
Journal:  J Am Geriatr Soc       Date:  2016-03       Impact factor: 5.562

4.  Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001-2013.

Authors:  Marcela Guevara; Carmen Ezpeleta; Alberto Gil-Setas; Luis Torroba; Xabier Beristain; Aitziber Aguinaga; José Javier García-Irure; Ana Navascués; Manuel García-Cenoz; Jesús Castilla
Journal:  Vaccine       Date:  2014-03-25       Impact factor: 3.641

5.  Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased?

Authors:  Xavier Vallès; Angeles Marcos; Mariona Pinart; Raquel Piñer; Francesc Marco; Josep Maria Mensa; Antoni Torres
Journal:  Chest       Date:  2006-09       Impact factor: 9.410

6.  Missed opportunities in antipneumococcal vaccination. Can something more be done for prevention?

Authors:  Mercedes Arencibia Jiménez; Juan Francisco Navarro Gracia; José Antonio Delgado de Los Reyes; Gerardo Pérez Torregrosa; David López Parra; Pilar López García
Journal:  Arch Bronconeumol       Date:  2013-12-07       Impact factor: 4.872

7.  Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients.

Authors:  Mariano Esperatti; Miquel Ferrer; Anna Theessen; Adamantia Liapikou; Mauricio Valencia; Lina Maria Saucedo; Elisabeth Zavala; Tobias Welte; Antoni Torres
Journal:  Am J Respir Crit Care Med       Date:  2010-08-06       Impact factor: 21.405

8.  Emerging non-13-valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in Spain.

Authors:  A González-Díaz; J Càmara; M Ercibengoa; E Cercenado; N Larrosa; M D Quesada; D Fontanals; M Cubero; J M Marimón; J Yuste; C Ardanuy
Journal:  Clin Microbiol Infect       Date:  2019-11-19       Impact factor: 8.067

9.  Invasive pneumococcal disease in children and adults in seven Italian regions after the introduction of the conjugate vaccine, 2008-2014.

Authors:  Fortunato D'Ancona; Maria Grazia Caporali; Martina Del Manso; Cristina Giambi; Romina Camilli; Fabio D'Ambrosio; Maria Del Grosso; Stefania Iannazzo; Elvira Rizzuto; Annalisa Pantosti
Journal:  Epidemiol Prev       Date:  2015 Jul-Aug       Impact factor: 1.901

10.  Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia.

Authors:  Marco Falcone; Alessandro Russo; Maddalena Giannella; Roberto Cangemi; Maria Gabriella Scarpellini; Giuliano Bertazzoni; José Martínez Alarcón; Gloria Taliani; Paolo Palange; Alessio Farcomeni; Annarita Vestri; Emilio Bouza; Francesco Violi; Mario Venditti
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

View more
  1 in total

1.  Economic Burden of Pneumococcal Disease in Individuals Aged 15 Years and Older in the Liguria Region of Italy.

Authors:  Matteo Astengo; Chiara Paganino; Daniela Amicizia; Cecilia Trucchi; Federico Tassinari; Camilla Sticchi; Laura Sticchi; Andrea Orsi; Giancarlo Icardi; Maria Francesca Piazza; Bruno Di Silverio; Arijita Deb; Francesca Senese; Gian Marco Prandi; Filippo Ansaldi
Journal:  Vaccines (Basel)       Date:  2021-11-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.